On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Subscribe To Our Newsletter & Stay Updated
